<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Toward Valid Generative Clinical Trial Data with Survival Endpoints - Health AI Hub</title>
    <meta name="description" content="This paper introduces a novel Variational Autoencoder (VAE) for generating synthetic clinical trial data, specifically addressing the complex challenge of time-">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>Toward Valid Generative Clinical Trial Data with Survival Endpoints</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2511.16551v1" target="_blank">2511.16551v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-11-20
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Perrine Chassat, Van Tuan Nguyen, Lucas Ducrot, Emilie Lanoy, Agathe Guilloux
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> cs.LG, stat.AP, stat.ME, stat.ML
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 0.95 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2511.16551v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="https://arxiv.org/pdf/2511.16551v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">This paper introduces a novel Variational Autoencoder (VAE) for generating synthetic clinical trial data, specifically addressing the complex challenge of time-to-event outcomes with censoring. The VAE jointly models mixed-type covariates and survival data without assuming independent censoring, outperforming GAN baselines in fidelity, utility, and privacy for data sharing and control-arm augmentation scenarios.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>This research offers a promising approach to accelerate clinical trials, reduce costs, and address patient recruitment challenges by enabling the creation of high-fidelity synthetic control arms, particularly crucial for late-phase oncology and rare disease studies where real patient data is scarce and expensive.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>The AI application is the generation of synthetic clinical trial data, specifically synthetic control arms and survival outcomes, using a Variational Autoencoder (VAE). This aims to improve the efficiency, cost-effectiveness, and data privacy of clinical trials. It enables data sharing under privacy constraints and augments control groups to address imbalances, directly impacting medical research design and execution.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>Addresses critical challenges in clinical trials, particularly the generation of time-to-event survival outcomes under censoring and small sample sizes for synthetic control arms in oncology and rare diseases.</li>
                    
                    <li>Proposes a novel Variational Autoencoder (VAE) framework that jointly generates mixed-type patient covariates and survival outcomes within a unified latent space.</li>
                    
                    <li>A key methodological advancement is the VAE's ability to model survival outcomes without the restrictive assumption of independent censoring, a significant limitation of prior GAN-based approaches.</li>
                    
                    <li>Evaluated across synthetic and real trial datasets in two realistic scenarios: private data sharing (synthetic data substitution) and control-arm augmentation (mitigating group imbalances).</li>
                    
                    <li>Demonstrated superior performance over GAN baselines in fidelity, utility, and privacy metrics across evaluated scenarios.</li>
                    
                    <li>Revealed a significant issue of systematic miscalibration in type I error and statistical power when using synthetic data, prompting the development of a post-generation selection procedure.</li>
                    
                    <li>The post-generation selection procedure successfully improved the calibration of statistical metrics, highlighting both progress and ongoing challenges in generative survival modeling.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>The authors developed a Variational Autoencoder (VAE) designed to jointly generate mixed-type patient covariates (e.g., demographic, clinical features) and time-to-event survival outcomes. This VAE operates within a unified latent variable framework, allowing for complex dependencies between covariates and survival, crucially without making the restrictive assumption of independent censoring, which is a common limitation in survival analysis and prior generative models like GANs. The model's performance was evaluated against GAN baselines using fidelity, utility, and privacy metrics on both synthetic and real trial datasets.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>The VAE-based generative model consistently outperformed existing GAN baselines across metrics of data fidelity (how closely synthetic data resembles real data), utility (how well models trained on synthetic data perform), and privacy. A critical finding was the identification of systematic miscalibration of statistical metrics, specifically type I error and power, when using the generated survival data. This issue was partially mitigated by a novel post-generation selection procedure, which improved the calibration of these statistical properties.</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>This methodology has the potential to significantly impact clinical trial efficiency by enabling the creation of synthetic control arms, thereby reducing the need for extensive real patient enrollment, lowering trial costs, and accelerating drug development. It is particularly valuable for conditions with small or fragmented patient populations, such as rare diseases and specific oncology indications, where obtaining sufficient real control data is challenging. The ability to share synthetic data also improves data utility under strict privacy constraints.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>Despite advances, the paper highlights "open challenges for generative survival modeling," particularly the systematic miscalibration of type I error and power in the generated data, which required a post-generation selection procedure to improve. This suggests that achieving perfectly calibrated statistical properties from synthetic survival data remains a complex task.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>While not explicitly detailed as future work, the development of the post-generation selection procedure indicates a direction towards refining the statistical calibration of synthetic survival data. Further research is implied to fully address the identified systematic miscalibration of type I error and power, suggesting avenues for developing more robust generative models or advanced post-processing techniques to ensure the statistical validity of synthetic clinical trial data.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Oncology</span>
                    
                    <span class="tag">Rare Diseases</span>
                    
                    <span class="tag">Clinical Trial Design</span>
                    
                    <span class="tag">Biostatistics</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">Generative AI</span>
                    
                    <span class="tag tag-keyword">Synthetic Data</span>
                    
                    <span class="tag tag-keyword">Clinical Trials</span>
                    
                    <span class="tag tag-keyword">Survival Analysis</span>
                    
                    <span class="tag tag-keyword">Variational Autoencoder (VAE)</span>
                    
                    <span class="tag tag-keyword">Time-to-Event Outcomes</span>
                    
                    <span class="tag tag-keyword">Censoring</span>
                    
                    <span class="tag tag-keyword">Oncology</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">Clinical trials face mounting challenges: fragmented patient populations, slow enrollment, and unsustainable costs, particularly for late phase trials in oncology and rare diseases. While external control arms built from real-world data have been explored, a promising alternative is the generation of synthetic control arms using generative AI. A central challenge is the generation of time-to-event outcomes, which constitute primary endpoints in oncology and rare disease trials, but are difficult to model under censoring and small sample sizes. Existing generative approaches, largely GAN-based, are data-hungry, unstable, and rely on strong assumptions such as independent censoring. We introduce a variational autoencoder (VAE) that jointly generates mixed-type covariates and survival outcomes within a unified latent variable framework, without assuming independent censoring. Across synthetic and real trial datasets, we evaluate our model in two realistic scenarios: (i) data sharing under privacy constraints, where synthetic controls substitute for original data, and (ii) control-arm augmentation, where synthetic patients mitigate imbalances between treated and control groups. Our method outperforms GAN baselines on fidelity, utility, and privacy metrics, while revealing systematic miscalibration of type I error and power. We propose a post-generation selection procedure that improves calibration, highlighting both progress and open challenges for generative survival modeling.</p>
            </section>

            
            <section class="paper-section">
                <h2>Comments</h2>
                <p>P. Chassat and V.T. Nguyen contributed equally to this work</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Journal Reference</h2>
                <p>Machine Learning for Health (ML4H) 2025</p>
            </section>
            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>